CYP2B6 Q172H 和 K262R基因多态性对乳腺癌患者环磷酰胺化疗预后的影响

 目的 探讨CYP2B6 Q172H和K262R基因多态性与乳腺癌环磷酰胺类药物辅助化疗预后的关系。方法 100例确诊的乳腺癌患者，采用环磷酰胺类药物为主的方案进行辅助化疗；用聚合酶链反应-连接酶检测反应检测CYP2B6 Q172H和K262R基因多态。结果 100例乳腺癌患者中，携带 Q172H(516G>T) GG、GT和TT基因型的患者分别占59%、38%和3%；携带K262R(785A>G) AA、AG和GG基因型的分别占47%、43%和10%。携带Q172H GT和TT基因型的患者无复发生存率显著高于携带GG 基因型的患者(P<0.05)；携带K262R AG和GG基因型的患者无复发生存率显著高于携带AA基因型的患者。多因素分析结果显示，Q172H 多态是影响患者复发的独立危险因素（P<0.05)。结论 Q172H GT和TT基因多态与接受环磷酰胺药物辅助化疗的乳腺癌患者的预后有关。

Prognostic Impact of CYP286 Q172H and K262R Polymorphism on Breast Cancer Patients Treated with Cyclophosphamide-based Adjuvant Chemotherapy

Abstract: Objective to study the effect of rotary magnetic field (RMF) combining 5-Fu on the cycle and apoptosis of mouse cell line SP2/0 in vitro.Methods SP2/0 cells were randomly divided into four groups: control group (N), 5-Fu group (C), magnetic group (M) and magnetic combining 5-Fu group (M+C).The M and M+C groups were treated with a RMF for two hours once a day.On day 4, the C and M+C groups were treated with 5-Fu 20 μg/ml.On day 5, cell cycle and apoptosis were measured by the flow cytometric (FCM).Results The S phase proportion of the M group and the G1 phase proportion of the C group were higher than that of the other three groups（P<0.05）.The S phase proportion of the M+C group decreased and lower than that of the M group，but was still higher than that of the N and C groups（P<0.05）.There was no significant difference in apoptosis rates between the N and M groups（P>0.05）.The apoptosis rates of the C and M+C groups were remarkedly higher than those of the N and M groups and the M+C group had the highest apoptosis rate.Conclusion The RMF cant induce the apoptosis.But it can enhance the cytotoxicity of 5-Fu and promote the cell apoptosis.The mechanism of the apoptosis may be related to SP2/0 cell line arrested at S phase.Objective To investigate the association of CYP2B6 Q172H and K262R polymorphisms with clinical outcome of breast cancer patients treated with cyclophosphamide based adjuvant chemotherapy.Methods A total of 100 patients with breast cancer were recruited.All patients received cyclophosphamide based adjuvant chemotherapy.PCR LDR (ligation detection reaction) method was used to detect genotypes of CYP2B6 Q172H and K262R.Results Of the 100 patients, the prevalence of the Q172H(516G>T) GG,GT and TT genotype was 59%,38% and 3%, respectively, and the frequencies of K262R(785A>G) AA,AG and GG genotype was 47%,43% and 10%,respectively.The recurrence free survival rate in patients with Q172H GT and TT genotype were significantly higher than those in patient s with GG genotype （P<0.05).Also, the recurrence free survival rate in patient s with K262R AG and GG genotype were significantly higher than those in patient s with AA genotype (P<0.05).However, multivariable analysis showed that only Q172H GT and TT genotype were associated with shorter recurrence free survival (P<0.05).Conclusion Polymorphism of Q172H GT and TT may be a potential prognostic factor in breast cancer patients treated with cyclophosphamide based adjuvant chemotherapy.